dc.contributor.author | Gonen, MUSTAFA SAİT | |
dc.contributor.author | PIRAGS, V. | |
dc.contributor.author | EL DAMASSY, H. | |
dc.contributor.author | DABROWSKI, M. | |
dc.contributor.author | RACICKA, E. | |
dc.contributor.author | MARTINKA, E. | |
dc.contributor.author | GIACONIA, J. | |
dc.contributor.author | STEFANSKI, A. | |
dc.date.accessioned | 2021-03-03T17:47:42Z | |
dc.date.available | 2021-03-03T17:47:42Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | PIRAGS V., EL DAMASSY H., DABROWSKI M., Gonen M. S. , RACICKA E., MARTINKA E., GIACONIA J., STEFANSKI A., "Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, cilt.66, sa.11, ss.1033-1041, 2012 | |
dc.identifier.issn | 1368-5031 | |
dc.identifier.other | av_4b7c1daf-a370-4167-acc5-13d68671cfc1 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/54164 | |
dc.identifier.uri | https://doi.org/10.1111/j.1742-1241.2012.03001.x | |
dc.description.abstract | Aims: The choice of insulin at initiation in type 2 diabetes remains controversial. The aim of this study was to assess the occurrence of self-reported severe hypoglycaemia associated with premixed insulin analogues in routine clinical care. Methods: A 12-month, prospective, observational, multicentre study in patients starting a commonly prescribed premixed insulin analogue (either insulin lispro 25/75 or biphasic insulin aspart 30/70, twice daily) after suboptimal glycaemic control on oral antidiabetic agents. Treatment decisions were made solely in the course of usual practice. Results: Study follow-up was completed by 991 (85.5%) of the 1150 patients enrolled. At baseline, mean (SD) age was 57.9 (10.1) years; mean diabetes duration was 9.2 (5.9) years; mean haemoglobin A1c (HbA1c) was 9.9 (1.8) % and the rate of severe hypoglycaemia was 0.03 episode/patient-year. At 12 months, the rate of severe hypoglycaemia was 0.04 episode/patient-year (95% CI 0.023, 0.055 episode/patient-year) and mean insulin dose was 41.5 (19.4) units. Changes from baseline to 12 months for mean fasting plasma glucose and HbA1c were -5.1 mmol/l and -2.5%, respectively. Conclusions: After initiation of premixed insulin analogues in patients with type 2 diabetes in real-world settings, the incidence of severe hypoglycaemia was lower than expected from previously reported studies. | |
dc.language.iso | eng | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | TIP, GENEL & İÇECEK | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.title | Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings | |
dc.type | Makale | |
dc.relation.journal | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | |
dc.contributor.department | University of Latvia , , | |
dc.identifier.volume | 66 | |
dc.identifier.issue | 11 | |
dc.identifier.startpage | 1033 | |
dc.identifier.endpage | 1041 | |
dc.contributor.firstauthorID | 104306 | |